Diabetes patients on insulin sensitizers have lower PAD risk

06/12/2013 | Medscape (free registration)

Data on 1,479 patients with type 2 diabetes and stable coronary disease revealed 24.1% of those who received insulin-providing medications to regulate blood glucose levels developed peripheral arterial disease at 4.6 years, compared with 16.9% in those who took insulin-sensitizing drugs. Researchers also found patients on insulin sensitizers showed reduced rates of amputation, lower-extremity revascularization and low ankle-brachial index than those who received insulin-providing drugs. The results appear in Diabetes Care.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ